Boston Pharmaceuticals products

BOS161721 (avizakimab) is a fully human anti-IL-21 antibody.

BOS-475 is a selective BET (bromodomain and extra terminal) inhibitor. BOS-475 potently inhibits multiple clinically validated pathways (IL-12/IL-23-p40, Th17 cytokines and TNF) relevant to psoriasis pathophysiology. BOS-475 demonstrates broad inhibitory activities on other key disease-relevant immune-inflammatory mediators such as MCP-1, IL-6, and CXCL10 & 11. Topical BOS-475 is a potential treatment for psoriasis and other inflammatory skin diseases.

BOS-421 is a highly selective, brain penetrant RIPK1 inhibitor.

BOS-228 is a novel monobactam for infections caused by multidrug-resistant carbapenem-resistant Enterobacteriaceae.

BOS-572 is a broad-spectrum serine beta-lactamase inhibitor (BLI) of the diazabicyclooctane (DBO) class.

BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas.

BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector function.

BOS-342 is a bispecific antibody comprised of an anti-GPC3 antagonistic antibody linked to a 4-1BB (CD137) agonistic anticalin protein.

BOS-704 is a ghrelin O-acyl transferase inhibitor with therapeutic potential for multiple indications.